New FDA Recall: These Birth Control Pills Are Under Investigation

Many of us have confidence in the intentions of the prescription drugs we receive. However, there are instances when our physicians cannot predict potential complications that might arise in the future. This is where the U.S. Food and Drug Administration (FDA) plays a role by consistently notifying the public about any issues pertaining to the medications they are using.

In April, the agency made known a significant recall affecting more than 80 prescription and over-the-counter drugs, including thyroid medication, due to uncertainties about their safety. Presently, the FDA is cautioning that a fresh issue with birth control prescriptions could be endangering a larger number of individuals. 

Continue reading to discover additional details about the recall of specific birth control pills due to the potential low effectiveness of the pill.

1. New FDA Recall of One of the Common Prescription Drugs

For those who are using contraceptive pills, it is important to take note of a recent advisory issued by the FDA. In a press release dated July 31, the agency informed the public about a significant recall of certain medications. 

The announcement stated that Lupin Pharmaceuticals Inc. has taken the voluntary step of recalling a portion of its Tydemy tablets that have been distributed to consumers via drug stores and other outlets.

The company elaborated on the nature of Tydemy, describing it as an oral contraceptive designed for women to prevent pregnancy and to elevate folate levels in those who opt for a similar contraceptive method for birth control, as stated in their recall notice.

2. Lupin Pharmaceuticals Reported the Unsafety of Two Tydemy Lots

Lupin Pharmaceuticals Inc. ranks among the largest pharmaceutical enterprises in the United States based on the aggregate number of prescribed drugs. The company is initiating a recall of two batches of Tydemy, both of which were dispersed throughout the entire country to various entities such as wholesalers, drug stores, mail-order pharmacies, and supermarkets. 

Tydemy is presented in blister packs designed for a 28-day cycle. A single blister of this kind was subsequently enclosed within a pouch, accompanied by a printed sleeve, a package insert, and a sachet containing an oxygen-absorbing substance. 

These three pouches were then grouped together within a sole carton. The birth control pills subject to the FDA recall possess a UPC of 368180904731 and underwent distribution during the timeframe spanning from June 2022 to May 2023.

3. The Effectiveness of the Pill Is Questionable

The recall of these contraceptive pills is prompted by test results that deviate from the specified standards at the 12-month stability assessment point. These results encompass any outcomes that do not meet the criteria outlined in pharmaceutical submissions, drug referential documents, authorized hardcover editions, or those established by the producer.

Upon conducting tests, it was determined that one of the recalled products exhibited a deficiency in the passive component ascorbic acid, while simultaneously displaying an elevated presence of a recognized contaminant.

These circumstances could potentially decrease the effectiveness of the pill. Lupin’s decision to recall these particular batches is motivated by the potential ramifications of a notable reduction in the quantity of inactive content. 

Such a situation could potentially compromise the product’s effectiveness, leading to the unforeseen possibility of failed birth control, thus an unintended pregnancy.

4. Consult Your Physician If You Take the Recalled Products

Wholesalers, distributors, and drug stores in possession of any of the recalled birth control pills are being directed to cease their sale without delay. However, if you are presently using these contraceptive pills, it is recommended that you continue to do so until you have consulted your healthcare provider.

Individuals who are currently on Tydemy medication are advised to maintain their regimen and promptly reach out to their pharmacist, doctor, or healthcare provider for guidance on potential alternative treatments.

No reports of unfavorable incidents linked to either of the recalled Tydemy batches have been received by the company thus far. Nonetheless, individuals should ask for guidance if they have encountered any issues possibly associated with the consumption or use of these prescription drugs.

Bottom Line

To sum up, concerns over the efficacy of specific batches of the Tydemy oral contraceptive led the FDA to issue a recall. Lupin Pharmaceuticals Inc. voluntarily initiated the recall after test results indicated potential deviations in stability and ingredient levels. 

While no adverse events have been reported, those with the recalled product are advised to discontinue sales and consult a healthcare provider for guidance. Users are encouraged to continue taking the medication until they discuss alternatives with their doctors.